Initial severity and efficacy of risperidone in autism: Results from the RUPP trial

European Psychiatry

Volumn 32, Issue , 2016, Pages 16-20

  Levine, S Z ^a   Kodesh, A ^a   Goldberg, Y ^a   Reichenberg, A ^b   Furukawa, T A ^c   Kolevzon, A ^b   Leucht, S ^d  

^a UNIVERSITY OF HAIFA   (Israel)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Autism; Baseline severity; Clinical trial; Outcome; Placebo; Psychopharmacology

Indexed keywords

PLACEBO; RISPERIDONE; NEUROLEPTIC AGENT;

ADOLESCENT; ANGER; ARTICLE; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER ASSESSMENT; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; IRRITABILITY; LETHARGY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SYMPTOM; AGGRESSION; AUTISTIC DISORDER; DRUG EFFECTS; DRUG MONITORING; FEMALE; MALE; PRESCHOOL CHILD; PSYCHOLOGY; SELF-INJURIOUS BEHAVIOR; TREATMENT OUTCOME;

ADOLESCENT; AGGRESSION; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; IRRITABLE MOOD; MALE; RISPERIDONE; SELF-INJURIOUS BEHAVIOR; TREATMENT OUTCOME;

EID: 84959329529     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2015.11.004     Document Type: Article

References (27)

1. Bailey A., Phillips W., Rutter M. Autism: towards an integration of clinical, genetic, neuropsychological, and neurobiological perspectives. J Child Psychol Psychiatry 1996, 37(1):89-126.
2. Baio J. Prevalence of autism spectrum disorders: autism and developmental disabilities monitoring network, 14 sites, United States, 2008. Morbidity and mortality weekly report. Surveillance summaries. Volume 61, Number 3 2012, Centers for Disease Control and Prevention.
3. Estes A., Olson E., Sullivan K., Greenson J., Winter J., Dawson G., et al. Parenting-related stress and psychological distress in mothers of toddlers with autism spectrum disorders. Brain Dev 2013, 35(2):133-138.
4. Findling R.L. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. J Clin Psychiatry 2005, 66(Suppl. 10):26-31.
5. Spencer D., Marshall J., Post B., Kulakodlu M., Newschaffer C., Dennen T., et al. Psychotropic medication use and polypharmacy in children with autism spectrum disorders. Pediatrics 2013, 132(5):833-840.
6. Aman M.G., Lam K.S., Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord 2003, 33(5):527-534.
7. Khan A., Brodhead A.E., Kolts R.L., Brown W.A. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005, 39(2):145-150.
8. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., Johnson B.T. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008, 5(2):e45.
9. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 303(1):47-53.
10. Melander H., Salmonson T., Abadie E., van Zwieten-Boot B. A regulatory apologia - a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 2008, 18(9):623-627.
11. Gibbons R.D., Hur K., Brown C.H., Davis J.M., Mann J.J. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012, 69:572-579.
12. Furukawa T.A., Levine S.Z., Tanaka S., Goldberg Y., Samara M., Davis J.M., et al. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 2015, 72(1):14-21.
13. King B.H., Dukes K., Donnelly C.L., Sikich L., McCracken J.T., Scahill L., et al. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatrics 2013, 167(11):1045-1052.
14. Arnold L.E., Farmer C., Kraemer H.C., Davies M., Witwer A., Chuang S., et al. Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol 2010, 20(2):83-93.
15. McCracken J.T., McGough J., Shah B., Cronin P., Hong D., Aman M.G., et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002, 347(5):314-321.
16. McDougle C.J., Scahill L., McCracken J.T., Aman M.G., Tierney E., Arnold L.E., et al. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am 2000, 9(1):201-224.
17. Guy W. Clinical Global Impression Scale. The ECDEU assessment manual for psychopharmacology-revised volume DHEW Publ. No. ADM 76. 1976;338:218-22.
18. Aman M.G., Singh N.N., Stewart A.W., Field C.J. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985, 89(5):485-491.
19. Arnold L.E., Vitiello B., McDougle C., Scahill L., Shah B., Gonzalez N.M., et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003, 42(12):1443-1450.
20. Hedeker D., Gibbons R.D. Longitudinal data analysis 2006, John Wiley & Sons, Inc., Hoboken, New Jersey.
21. Schwarz G., Gideon E. Estimating the dimension of a model. Ann Stat 1978, 6(2):461-464.
22. Ihaka R., Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat 1996, 5(3):299-314.
23. Pinheiro J., Bates D., DebRoy S., Sarkar D., R Core Team nlme: linear and nonlinear mixed-effects models. R package version 3. 1-117 2014, R Foundation for Statistical Computing, Vienna.
24. Furukawa T.A., Leucht S. How to obtain NNT from Cohen's d: comparison of two methods. PloS One 2011, 6(4):e19070.
25. Fernandez-Mayoralas D.M., Fernandez-Jaen A., Munoz-Jareno N., Calleja-Perez B., Fernandez-Perrone A.L., Arribas S.L. Treatment with paliperidone in children with behavior disorders previously treated with risperidone: an open-label trial. Clin Neuropharmacol 2012, 35(5):227-230.
26. Wilder J. The law of initial value in neurology and psychiatry; facts and problems. J Nerv Ment Dis 1957, 125(1):73-86.
27. Cohen J. Statistical power analysis in the behavioral sciences 1988, Erlbaum, Hillsdale, NJ.